Ophthalmic compositions comprising povidone-iodine
View Patent ↗A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient.
1. An ophthalmic composition suitable for topical administration to an eye, comprising a mixture of
a) povidone-iodine in a concentration between 0.01% and 10% by weight, and
b) a steroid, wherein the steroid is dexamethasone, and wherein, after a period of one month after mixing the steroid and povidone-iodine to form the composition, the steroid concentration is at least 90% by weight of the steroid starting concentration.
2. The ophthalmic composition of claim 1 wherein said povidone-iodine is between 0.1% and 2.5% by weight.
3. The ophthalmic composition of claim 1 wherein said povidone-iodine is between 0.5% and 2% by weight.
4. The ophthalmic composition of claim 1 wherein a total weight of said povidone-iodine and said steroid is between 0.1% and 4.5% in said composition.
5. The ophthalmic composition of claim 1 wherein said steroid is at a concentration of between 0.01 and 10%.
6. The ophthalmic composition of claim 1 wherein said steroid is at a concentration of between 0.05 and 2%.
7. The ophthalmic composition of claim 1 wherein said composition further comprises an antimicrobial preservative.
8. The ophthalmic composition of claim 7 wherein said antimicrobial preservative is selected from the group consisting of benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, EDTA, sorbic acid, polyquarternium 1 and a combination thereof.
9. The ophthalmic composition of claim 7 wherein said antimicrobial preservative is at a concentration of about 0.001% to 1.0% by weight in said composition.
10. The ophthalmic composition of claim 1 wherein said composition further comprises a co-solvent/surfactant.
11. The ophthalmic composition of claim 10 wherein said co-solvent/surfactant is selected from the group consisting of polysorbate 20, polysorbate 60, polysorbate 80, Pluronic F-68, Pluronic F-84, Pluronic P-103, cyclodextrin, tyloxapol and a combination thereof.
12. The ophthalmic composition of claim 10 wherein said co-solvent/surfactant is at a concentration of about 0.01% to 2% by weight in said composition.
13. The ophthalmic composition of claim 1 wherein said composition further comprises a viscosity increasing agent.
14. The ophthalmic composition of claim 13 wherein said viscosity increasing agent is selected from the group consisting of polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose, and a combination thereof.
15. The ophthalmic composition of claim 13 wherein said viscosity increasing agent is at a concentration of about 0.01% to 2% by weight in said composition.
16. The ophthalmic composition of claim 1 , wherein said composition is in the form of a solution, suspension, emulsion, ointment, cream, gel, or a controlled-release/sustain-release vehicle.
17. The ophthalmic composition of claim 1 , comprising: 0.5 to 2% (w/w) polyvinylpyrrolidinone-iodine complex; 0.05 to 2% (w/w) steroid; 0.005% to 0.02% (w/w) EDTA; 0.01 to 0.5% (w/w) sodium chloride; 0.02 to 0.1% (w/w) tyloxapol; 0.5% to 2% (w/w) sodium sulfate; and 0.1 to 0.5% (w/w) hydroxyethylcellulose.
18. The ophthalmic composition of claim 1 , comprising: 1.0% (w/w) polyvinylpyrrolidinone-iodine complex; 0.1% (w/w) steroid; 0.01% (w/w) EDTA; 0.3% (w/w) sodium chloride salt; 0.05% (w/w) tyloxapol; 1.2% (w/w) sodium sulfate; and 0.25% (w/w) hydroxyethylcellulose.
19. The ophthalmic composition of claim 1 wherein said composition retains 90% of its polyvinylpyrrolidinone-iodine and 90% of its steroid after a period of 3 months in a lighted environment.
20. The ophthalmic composition of claim 1 wherein said composition retains 90% of its polyvinylpyrrolidinone-iodine and 90% of its steroid after a period of 1 year in a lighted environment.
21. The ophthalmic composition of claim 1 wherein said composition is an aqueous solution.